Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it’s virtually impossible to tell exactly which pills, shots and treatments within a firm’s pipeline will eventually evolve into cash flows, let alone blockbuster cash cows. With many clinical trials to pass, even a promising late-stage candidate can still fall flat. Biotech investors may wish to play the odds game regarding a biotech innovator’s pipeline. Some treatments will ge ...